DIVIS LAB

rose after global brokerage Citi turned upbeat on the stock, flagging attractive valuations and sector tailwinds. Citi reiterated its buy call with a price target of Rs 7,750, implying nearly 28.5 percent upside from the last close of Rs 6,028 per share on the NSE. The brokerage said the recent weakness in the stock offers a good entry point, dismissing concerns around Orforglipron, Eli Lilly’s oral GLP-1 candidate. It noted that even with consensus sales estimates of over $15 billion by 2030, Divi’s is still positioned to clock $200–300 million in intermediate supplies.